anti-TNF-IR phase III

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005330-20

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To determine the efficacy and safety of ocrelizumab versus placebo in reducing signs and symptoms of rheumatoid arthritis (RA), when used in combination with methotrexate (MTX) or leflunomide given either alone or in combination with other non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) in patients with active RA who have an inadequate response to at least one anti-TNF-α therapy.


Critère d'inclusion

  • Rheumatoid Arthritis